$CNTX News
Last published 1d ago
- 1d agoCNTXContext Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline ProgressGlobeNewswireCTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months
- 2mo agoCNTXContext Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202GlobeNewswireCT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA,
- 3mo agoCNTXContext Therapeutics Reports Second Quarter 2026 Operating and Pipeline ProgressGlobeNewswirePrioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4
- 4mo agoCNTXContext Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePHILADELPHIA, July 10, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific
- 4mo agoCNTXContext Therapeutics Added to Russell 2000® and Russell 3000® IndexesGlobeNewswirePHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging
- 4mo agoCNTXContext Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76GlobeNewswire29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer ("PROC") who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome ("CRS") in PROC limited to
- 5mo agoCNTXContext Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePHILADELPHIA, June 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 5mo agoCNTXContext Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswirePHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 5mo agoBCABCNTXContext Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202GlobeNewswireContext announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18,
- 6mo agoCNTXContext Therapeutics Reports First Quarter 2026 Operating and Financial ResultsGlobeNewswirePhase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202 (Nectin-4 x CD3)
- 7mo agoCNTXNEOGNeogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board SecretaryBusiness WireNeogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an
- 7mo agoCNTXContext Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian CancerGlobeNewswireFast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02, 2026 (GLOBE
- 7mo agoCNTXContext Therapeutics Reports Full Year 2025 Operating and Financial ResultsGlobeNewswirePhase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million
- 9mo agoCNTXContext Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 9mo agoCNTXContext Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 11mo agoCNTXIMNMONCYPRLD+1Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval StandardsGlobeNewswireVANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster
- 1y agoCNTXContext Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual MeetingGlobeNewswirePHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies
- 1y agoCNTXContext Therapeutics Reports Third Quarter 2025 Operating and Financial ResultsGlobeNewswireOngoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9
- 1y agoCNTXSKYEStep Pharma announces the appointment of Dr Karen Smith as Chief Medical OfficerGlobeNewswireKaren Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's
- 1y agoCNTXContext Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 1y agoCNTXContext Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual MeetingGlobeNewswirePHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies
- 1y agoCNTXContext Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 1y agoCNTXContext Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 1y agoCNTXContext Therapeutics Reports Second Quarter 2025 Operating and Financial ResultsGlobeNewswireCTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027
- 1y agoCNTXContext Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO MeetingGlobeNewswireDosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.
- 1y agoCNTXContext Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerGlobeNewswirePHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 1y agoCNTXContext Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 1y agoCNTXContext Therapeutics Reports First Quarter 2025 Operating and Financial ResultsGlobeNewswireCTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA,
- 1y agoCNTXContext Therapeutics Announces Chief Medical Officer TransitionGlobeNewswirePHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid
- 1y agoCNTXContext Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual MeetingGlobeNewswirePreclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 30, 2025 (GLOBE
- 1y agoCNTXContext Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95GlobeNewswireCT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context's second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) -- Context
- 1y agoCNTXContext Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for
- 1y agoCNTXContext Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025GlobeNewswirePHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies
- 1y agoCNTXContext Therapeutics Reports Full Year 2024 Operating and Financial ResultsGlobeNewswireCTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA,
- 1y agoCNTXContext Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswirePHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that Context has
- 1y agoCNTXContext Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswirePHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company
- 1y agoCNTXContext Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76GlobeNewswireCTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.
- 1y agoCNTXContext Therapeutics Appoints Andy Pasternak as Chairman of the Board of DirectorsGlobeNewswireMr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, Jan. 13, 2025 (GLOBE
- 1y agoONCYERASALLOCNTX+1Oncology in Focus: How Emerging Therapies Are Reshaping Cancer TreatmentPR NewswireUSA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never before....
- 2y agoCNTXContext Therapeutics Reports Third Quarter 2024 Operating and Financial ResultsGlobeNewswireExpands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody Strengthens board with appointments of
- 2y agoCNTXContext Therapeutics to Participate in Upcoming Investor Conferences in NovemberGlobeNewswirePHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company
- 2y agoCNTXContext Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingGlobeNewswirePHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster
- 2y agoBCABCNTXBioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging AntibodyGlobeNewswireContext to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones
- 2y agoCNTXContext Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of DirectorsGlobeNewswirePHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced the appointments
- 2y agoCNTXContext Therapeutics Reports Second Quarter 2024 Operating and Financial ResultsGlobeNewswireAnnounced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07,
- 2y agoCNTXContext Therapeutics Appoints Chief Medical Officer and Vice President of Clinical OperationsGlobeNewswireCompany announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations Appointments support the development of the Company's two clinical-stage T cell engaging assets to
- 2y agoCNTXContext Therapeutics Acquires Phase 1-ready T cell Engager CT-95GlobeNewswireCT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE)
- 2y agoCNTXContext Therapeutics Reports First Quarter 2024 Operating and Financial ResultsGlobeNewswireAnnounced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context
- 2y agoCNTXContext Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76GlobeNewswireCTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics
- 2y agoCNTXContext Therapeutics Announces $100 Million Private PlacementGlobeNewswireFinancing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) --